β€’
May 31, 2021

AngioDynamics Q4 2021 Earnings Report

AngioDynamics experienced a strong fourth quarter with significant sales growth and improved gross margin.

Key Takeaways

AngioDynamics reported a strong Q4 2021 with a 31.7% increase in net sales compared to the prior-year quarter. The company's gross margin improved by 330 basis points year over year. The company is now trending close to normalized run rates. The company recorded a net loss of $19.5 million, or a loss per share of $0.51.

Net sales increased by 31.7% compared to the prior-year quarter.

Gross margin increased by 330 basis points year over year.

GAAP loss per share was $0.51, while adjusted earnings per share was $0.00.

Cash and cash equivalents were $48.2 million on May 31, 2021.

Total Revenue
$76.8M
Previous year: $58.3M
+31.7%
EPS
-$0.505
Previous year: -$0.06
+742.2%
Gross Margin
55.1%
Previous year: 51.8%
+6.4%
Gross Profit
$42.3M
Previous year: $30.2M
+40.1%
Cash and Equivalents
$48.2M
Previous year: $54.4M
-11.5%
Free Cash Flow
$3.1M
Previous year: $2.4M
+29.1%
Total Assets
$561M
Previous year: $594M
-5.5%

AngioDynamics

AngioDynamics

AngioDynamics Revenue by Geographic Location

Forward Guidance

The Company expects its fiscal year 2022 net sales to be in the range of $305 to $310 million, gross margin to be approximately 55.0% and adjusted earnings per share in the range of $0.00 to $0.05 as the Company continues to invest in new product launches to drive future growth.

Revenue & Expenses

Visualization of income flow from segment revenue to net income